SB Investment Advisers (UK) Ltd reported a sale of 2,168,884 shares of Vir Biotechnology (NASDAQ:VIR) in its May 15, 2026, SEC filing, an estimated $17.28 million trade based on quarterly average pricing.
What happened According to an SEC filing dated May 15, 2026, SB Investment Advisers (UK) Ltd reduced its stake in Vir Biotechnology by 2,168,884 shares during the first quarter
The estimated value of the shares sold was $17.28 million, calculated using the mean unadjusted closing price for the quarter. The quarter-end value of the position, including market movements, declined by $19.00 million. What else to know – Top holdings after the filing: – NYSE:CPNG: $5.47 billion (70.7% of AUM) – NASDAQ: GRAB: $1.47 billion (19.0% of AUM) – NASDAQ: RLAY: $277.65 million (3.6% of AUM) – NYSE: COMP: $160.85 million (2.1% of AUM) – NASDAQ:VIR: $98.09 million (1.3% of AUM) – – As of May 15, 2026, Vir Biotechnology shares were priced at $8.79, up 93% over the past year and outperforming the S&P 500’s roughly 25% gain in the same period.
Company overview Company snapshot – Vir Biotechnology develops monoclonal antibodies and RNA-based therapeutics targeting infectious diseases, including COVID-19 (Sotrovimab/Xevudy), hepatitis B (VIR-2218, VIR-3434), influenza A (VIR-2482), and HIV (VIR-1111). – The firm operates a research-driven business model, generating revenue through product sales, strategic collaborations, and licensing agreements with global pharmaceutical and biotechnology partners. – It serves healthcare providers, governments, and global health organizations focused on the treatment and prevention of serious infectious diseases. Vir Biotechnology, Inc. is a commercial-stage biotechnology company specializing in the development of innovative immunology-based therapies for infectious diseases. The company leverages strategic collaborations and advanced research capabilities to address unmet medical needs in global health.